Journalist Scott Carney argues in favor of gray-market peptides. Only the title is available, so watch for his full reasoning and treat any health claims with caution.
Recap by typeshit. Full story at Scott Carney.
Osbourne says any medicine can be misused and connects Ozempic to the body image struggles he had when he was younger.
A one-line stock move for the maker of Mounjaro and Zepbound, with no reason given for the gain.
The company announced exclusive manufacturing rights across its needle-free peptide products. Terms aren't given here.
The endocrinologist says fear, judgment and misinformation still shape how people see GLP-1 drugs, and asks patients to learn before deciding.
After his appetite disappeared on tirzepatide, Krasno talks with the Your Best Shot author about food and why scale weight can mask muscle, bone and testosterone loss.
BioPharma Dive reports the recall adds to safety worries about knockoff weight loss drugs, which stay popular despite FDA warnings and pressure from Lilly and Novo.
Loading…